MaxCyte is a clinical-stage global cell-based therapies and life sciences company. As the inventors of the premier cell-engineering enabling technology, the team at MaxCyte helps bring the promise of next-generation cell and gene-editing therapies to life. MaxCyte’s electroporation platform is currently being deployed by leading drug developers worldwide, including all of the top ten global biopharmaceutical companies and is used by leading genome engineering companies such as Sangamo, CRISPR Therapeutics, and Allogene.
In this virtual seminar at the Gladstone Institutes the MaxCyte team will highlight powerful case studies that demonstrate the successful use of MaxCyte’s clinically validated, scalable electroporation system in the pre-clinical and clinical scale cell engineering of primary cells, iPSCs, and iPSC derived cells (cardiomyocytes, neurons, etc.) with CRISPR RNPs & CARs.